2. Signaling Pathways
  3. Immunology/Inflammation
  4. NO Synthase

NO Synthase

Nitric oxide synthases; NOS

NO Synthase

Related Products

PDF 1.66 MB

Nitric oxide synthases (NOSs) are a family of enzymes catalyzing the production of nitric oxide (NO) from L-arginine. NO synthases catalyze the oxidation of L-arginine to NO and L-citrulline. Mammals contain three NOS isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). NO produced from these different NOS isoforms is involved in a wide range of physiologic functions in the nervous, immune, and cardiovascular systems. Unregulated NO production can lead to pathologic conditions such as stroke, inflammation, and hypertension. Therefore, the control of NOS activity by isoform selective NOS inhibitors has great potential for therapeutic treatments of NO-related diseases.

NO Synthase Isoform Specific Products:

NO Synthase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N6599
    3-Feruloylquinic acid
    		Inhibitor 98.98%
    3-Feruloylquinic acid (3-O-Feruloylquinic acid), a derivative of quinic acid-bound phenolic acid, shows antioxidant and anti-inflammatory activities.
    3-Feruloylquinic acid
  • HY-12124
    BBS-4
    		Inhibitor 99.51%
    BBS-4 is a potent and selective inducible nitric oxide synthase (NOS2) dimerization inhibitor, with an IC50 of 0.49 nM. BBS-4 can protect mice from the cardiovascular dysfunction of sepsis.
    BBS-4
  • HY-107208
    Procyanidol B4
    		Inhibitor 99.89%
    Procyanidol B4 ((-)-Procyanidin B4) is an orally active polyphenol found in Q.gilva. Procyanidol B4 exerts antioxidant activity by scavenging DPPH (HY-112053) (IC50: 12.15 μM) and Nitro blue tetrazolium chloride (NBT) (HY-15925) (IC50: 8.67 μM). Procyanidol B4 exhibits anti-inflammatory activity by inhibiting the expression of COX-2 and IL-1β and iNOS.
    Procyanidol B4
  • HY-12122A
    AR-C102222 hydrochloride
    		Inhibitor 99.83%
    AR-C102222 hydrochloride is a potent, competitive, orally active and highly selective inducible nitric oxide synthase (iNOS) inhibitor, with an IC50 of 37 nM. AR-C102222 hydrochloride has antinociception and anti-inflammatory activities.
    AR-C102222 hydrochloride
  • HY-N2008
    Luteolin 5-O-glucoside
    		Inhibitor ≥98.0%
    Luteolin 5-O-glucoside, a major flavonoidfrom Cirsium maackii, possesses anti-inflammatory activity. Luteolin 5-O-glucoside inhibits LPS-induced NO production and t-BHP-induced ROS generation. Luteolin 5-O-glucoside suppresses the expression of iNOS and COX-2 in macrophages.
    Luteolin 5-O-glucoside
  • HY-P0132
    YIGSR
    		Inhibitor 99.28%
    YIGSR is a peptide that can inhibit the tumour growth and metastasis of leukaemic cells. YIGSR blocks the cellular binding to laminin I via a 67-kDa laminin-binding protein, and inhibits shear-induced increase in eNOS expression of laminin cells.
    YIGSR
  • HY-W074890S
    Palmitoylglycine-d31
    		99.40%
    Palmitoylglycine-d31 is the deuterium labeled Palmitoylglycine.
    Palmitoylglycine-d<sub>31</sub>
  • HY-141411A
    Zevaquenabant
    		Antagonist 99.64%
    Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD).
    Zevaquenabant
  • HY-113216BS
    Asymmetric-dimethylarginine-d6 dihydrochloride
    		98.30%
    Asymmetric-dimethylarginine-d6 (dihydrochloride) is the deuterium labeled Asymmetric-dimethylarginine dihydrochloride.
    Asymmetric-dimethylarginine-d<sub>6</sub> dihydrochloride
  • HY-14928A
    Lobeglitazone sulfate
    		Inhibitor 99.63%
    Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate is the orally active agonist for PPAR with EC50 of 137.4 nM and 546.3 nM for PPARγ and PPARα. Lobeglitazone sulfate is the inhibitor for ERK/JNK/Smad/NF-κB signaling pathway. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties.
    Lobeglitazone sulfate
  • HY-N0385
    Gomisin J
    		Activator 99.87%
    Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc.
    Gomisin J
  • HY-N7064
    Iminostilbene
    		Inhibitor 99.34%
    Iminostilbene is a chemical precursor of carbamazepine. Additionally, Iminostilbene is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2). Iminostilbene exerts its effects by inhibiting PKM2 and its interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression, and decreasing LPS-induced release of IL-1β, IL-6, TNF-α, and MCP-1, thereby suppressing macrophage-mediated inflammatory responses and improving myocardial ischemia/reperfusion (MI/R) injury. Iminostilbene holds promise for research in inflammation regulation, cardiovascular diseases (such as MI/R injury), and macrophage-mediated immune-related diseases.
    Iminostilbene
  • HY-B1264
    Celiprolol hydrochloride
    		Activator 98.93%
    Celiprolol (REV 5320) is a potent, cardioselective and orally active β1-andrenoceptor r antagonist with partial β2 agonist activity, with Ki values of 0.14-8.3 μM. Celiprolol has antihypertensive and antianginal activity, and can be used for the research of cardiovascular disease such as high blood pressure.
    Celiprolol hydrochloride
  • HY-N7635
    Oleanolic acid 28-O-β-D-glucopyranoside
    		Inhibitor 99.42%
    Oleanolic acid 28-O-β-D-glucopyranoside (β-D-Glucopyranosyl oleanolate) is an orally active pentacyclic triterpenoid compound. Oleanolic acid 28-O-β-D-glucopyranoside has anti-inflammatory effects. In ulcerative colitis models, Oleanolic acid 28-O-β-D-glucopyranoside can inhibit the inflammatory response, enhance the intestinal epithelial barrier function, and modulate the gut microbiota. Its mechanism of action is related to the PI3K-AKT and MAPK signaling pathways. Oleanolic acid 28-O-β-D-glucopyranoside can be used in the research of diseases such as colitis.
    Oleanolic acid 28-O-β-D-glucopyranoside
  • HY-153832
    MSU-42011
    		Inhibitor 98.43%
    MSU-42011 is an orally active retinoid X receptor (RXR) agonist. MSU-42011 inhibits the iNOS activity and reduces the expression of p-ERK protein. MSU-42011 has immunomodulatory and antitumor activity.
    MSU-42011
  • HY-N0761A
    trans-Isoferulic acid
    		Inhibitor 99.93%
    trans-Isoferulic acid (trans-3-Hydroxy-4-methoxycinnamic acid) is an aromatic acid isolated from the roots of Clematis florida var. plena. trans-Isoferulic acid exhibits anti-inflammatory activity.trans-isoferulic acid suppresses NO and PGE2 production through the induction of Nrf2-dependent heme oxygenase-1 (HO-1).
    trans-Isoferulic acid
  • HY-130452
    NOS1-IN-1
    		Inhibitor
    NOS1-IN-1 is a selective and cell-permeable nNOS inhibitor with a Ki of 120 nM. NOS1-IN-1 exhibits 2617-fold and 325-fold selectivity over eNOS (Ki=39 μM) and iNOS (Ki=325 μM) , respectively. NOS1-IN-1 can be used for the research of neurological disease, including cerebral palsy (CP).
    NOS1-IN-1
  • HY-170621
    STAT1/3-IN-1
    		Inhibitor
    STAT1/3-IN-1 (Compound 6k) is a STAT1/3 phosphorylation inhibitor. STAT1/3-IN-1 inhibits the phosphorylation and nuclear translocation of STAT1/3. STAT1/3-IN-1 also inhibits inflammatory enzymes iNOS and COX-2. STAT1/3-IN-1 demonstrates anti-inflammatory effect (reduction of pro-inflammatory cytokines, including IL-1β, IL-6 and TNF-α) without significant cytotoxicity.
    STAT1/3-IN-1
  • HY-147306A
    (S)-ZLc002
    		Inhibitor ≥98.0%
    (S)-ZLc002 is a S-enantiomer of ZLc-002. ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain.
    (S)-ZLc002
  • HY-N8435
    Desoxo-narchinol A
    		Inhibitor ≥98.0%
    Desoxo-narchinol A is an orally active and potent anti-inflammatory agent. Desoxo-narchinol A can be isolated from the roots and rhizomes of Nardostachys jatamansi. Desoxo-narchinol A can be used for septic shock and inflammatory diseases research.
    Desoxo-narchinol A
Cat. No. Product Name / Synonyms Application Reactivity
NO Synthase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.